81 related articles for article (PubMed ID: 15866669)
21. Case 6: benefits and risks of OKT3 treatment in renal transplantation.
First MR
Transplantation; 2001 Sep; 72(6):1177-8. PubMed ID: 11584824
[No Abstract] [Full Text] [Related]
22. Infectious and non-infectious neurologic complications in heart transplant recipients.
Muñoz P; Valerio M; Palomo J; Fernández-Yáñez J; Fernández-Cruz A; Guinea J; Bouza E
Medicine (Baltimore); 2010 May; 89(3):166-175. PubMed ID: 20453603
[TBL] [Abstract][Full Text] [Related]
23. Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin.
Zhang R; Haverich A; Strüber M; Simon A; Bara C
J Heart Lung Transplant; 2008 Jun; 27(6):603-9. PubMed ID: 18503958
[TBL] [Abstract][Full Text] [Related]
24. Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry.
Crespo-Leiro MG; Alonso-Pulpón L; Arizón JM; Almenar L; Delgado JF; Palomo J; Manito N; Rábago G; Lage E; Diaz B; Roig E; Pascual D; Blasco T; de la Fuente L; Campreciós M; Vázquez de Prada JA; Muñiz J
J Heart Lung Transplant; 2007 Nov; 26(11):1105-9. PubMed ID: 18022075
[TBL] [Abstract][Full Text] [Related]
25. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL
Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164
[TBL] [Abstract][Full Text] [Related]
26. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
27. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.
Miller JT; Collins CD; Stuckey LJ; Luan FL; Englesbe MJ; Magee JC; Park JM
Pharmacotherapy; 2009 Oct; 29(10):1166-74. PubMed ID: 19792990
[TBL] [Abstract][Full Text] [Related]
28. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.
Ailawadi G; Smith PW; Oka T; Wang H; Kozower BD; Daniel TM; Kron IL; Jones DR
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):594-602. PubMed ID: 18329476
[TBL] [Abstract][Full Text] [Related]
29. Infectious complications in kidney transplant recipients: a single-center experience.
Charfeddine K; Zaghden S; Kharrat M; Kamoun K; Jarraya F; Hachicha J
Transplant Proc; 2005; 37(6):2823-5. PubMed ID: 16182820
[TBL] [Abstract][Full Text] [Related]
30. Intestinal transplantation in children: a summary of clinical outcomes and prognostic factors in 108 patients from a single center.
Kato T; Gaynor JJ; Selvaggi G; Mittal N; Thompson J; McLaughlin GE; Nishida S; Moon J; Levi D; Madariaga J; Ruiz P; Tzakis A
J Gastrointest Surg; 2005 Jan; 9(1):75-89; discussion 89. PubMed ID: 15623448
[TBL] [Abstract][Full Text] [Related]
31. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants.
Kee TY; Chapman JR; O'Connell PJ; Fung CL; Allen RD; Kable K; Vitalone MJ; Nankivell BJ
Transplantation; 2006 Jul; 82(1):36-42. PubMed ID: 16861939
[TBL] [Abstract][Full Text] [Related]
32. Prophylactic use of OKT3 in cardiac transplantation.
Konertz W; Weyand M; Friedl A
Transplant Proc; 1989 Feb; 21(1 Pt 3):2494-6. PubMed ID: 2495640
[No Abstract] [Full Text] [Related]
33. Early screening for antibody-mediated rejection in heart transplant recipients.
Kfoury AG; Hammond ME; Snow GL; Stehlik J; Reid BB; Long JW; Gilbert EM; Bader FM; Bull DA; Renlund DG
J Heart Lung Transplant; 2007 Dec; 26(12):1264-9. PubMed ID: 18096477
[TBL] [Abstract][Full Text] [Related]
34. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies.
Wissing KM; Fomegné G; Broeders N; Ghisdal L; Hoang AD; Mikhalski D; Donckier V; Vereerstraeten P; Abramowicz D
Transplantation; 2008 Feb; 85(3):411-6. PubMed ID: 18322434
[TBL] [Abstract][Full Text] [Related]
35. The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival.
Bond G; Reyes J; Mazariegos G; Wu T; Schaefer N; Demetris J; Fung JJ; Starzl TE; Abu-Elmagd K
Transplant Proc; 2000 Sep; 32(6):1197-8. PubMed ID: 10995904
[No Abstract] [Full Text] [Related]
36. Interdisciplinary development of an intravenous infusion protocol for Orthoclone OKT3.
Byrd JG; Raulinaitis A; Burke PB; Welsh D
J Intraven Nurs; 1996; 19(3):117-21. PubMed ID: 8788828
[TBL] [Abstract][Full Text] [Related]
37. Simulect induction significantly decreases CMV infection in kidney recipients compared to OKT3.
Kode RK; Kumar AM; Pankewycz O; Damask AM; Seirka D; Lam A; Phillips K; Ardron M; Brezin J; Chvala R; Kumar MS
Transplant Proc; 2001; 33(1-2):1268-9. PubMed ID: 11267286
[No Abstract] [Full Text] [Related]
38. Induction therapy in cardiac transplantation: when and why?
Baran DA
Heart Fail Clin; 2007 Jan; 3(1):31-41. PubMed ID: 17545007
[TBL] [Abstract][Full Text] [Related]
39. Neurologic complications of immunosuppressive agents.
Walker RW; Brochstein JA
Neurol Clin; 1988 May; 6(2):261-78. PubMed ID: 3138519
[TBL] [Abstract][Full Text] [Related]
40. Cancers following thoracic organ transplantation: a single center study.
Burtin P; Boman F; Pinelli G; Mattei MF; Dopff C; Villemot JP
Transplant Proc; 1995 Apr; 27(2):1765-6. PubMed ID: 7725493
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
